Boehringer Ingelheim, Re-Vana Therapeutics Partner on Long-Acting Ophthalmics

Boehringer Ingelheim and Re-Vana Therapeutics, a U.S. and UK based developer of ocular therapeutics and drug delivery technologies, entered a strategic collaboration and license agreement that aims to develop first-in-class extended-release therapies for eye diseases.

Boehringer aims to add up to three projects per year across therapeutic modalities. The companies will jointly oversee Re-Vana’s feasibility and development activities for the extended-release programs, with Boehringer Ingelheim assuming sole responsibility for clinical development, regulatory approval, and global commercialization of the products. The terms of the agreement grant Boehringer Ingelheim target exclusivity, and provide for upfront, development, regulatory and commercial milestone payments to Re-Vana, with total potential deal value exceeding $1 billion for the initial three targets, in addition to royalty payments on sales.

Re-Vana’s drug delivery technology is designed to release treatments slowly over six to 12 months, aiming to drastically reduce how often patients need injections. Lowering the treatment burden could lead to higher treatment compliance and potentially result in better therapeutic outcomes. Boehringer Ingelheim will explore combining this technology with its pipeline in eye health, which includes four assets in Phase II.

“We’re looking forward to team up with Re-Vana to push the boundaries of what’s possible in eye health,” said Nedim Pipic, Global Head of Mental Health, Eye Health and Emerging Areas at Boehringer Ingelheim. “Together, we want to tackle the limits of today’s treatments – aiming to help people keep their sight, with fewer injections. This partnership is a bold step forward in our mission to protect vision and ease the burden on patients.”

“The strategic collaboration with Boehringer Ingelheim marks a transformational moment for Re-Vana,” said Michael O’Rourke, Re-Vana Chief Executive Officer. “By combining our extended-release platform with Boehringer Ingelheim’s world-class research and development capabilities and eye health pipeline, we strive to bring forward a new generation of long-acting treatments for eye diseases that offer clinical and quality-of-life benefits for patients.”